Serum Adiponectin and Progranulin Levels are Associated with Gallstone Disease

Abstract

Background/Aim: Aberrant adipokine serum concentrations are associated with a variety of obesity-related diseases. This study was designed to investigate the putative role of the adipokines adiponectin, chemerin, progranulin, vaspin, fibroblast growth factor 21 (FGF21) and adipocyte fatty acid binding protein (AFABP) in gallstone disease.

Methods: Serum levels of adiponectin, chemerin, progranulin, vaspin, FGF21 and AFABP of 189 gallstone patients and 833 healthy controls were measured by enzyme-linked immunosorbent assays.

Results: Increased adiponectin levels were nominally associated with lower gallstone risk in women (p=0.036, odds ratio (OR) 0.47, 95% confidence interval (CI) [0.23; 0.95]). Furthermore progranulin serum concentrations in men were significantly elevated in gallstone carriers in comparison to controls (p=0.012, OR 6.1, 95% CI [1.5; 24.9]). Serum levels of chemerin, vaspin, FGF21 and AFABP did not differ between controls and subjects with gallstones.

Conclusion: Our data further support a protective effect of adiponectin on gallstone risk and suggest a role of progranulin in the pathophysiology of cholelithiasis. Nevertheless, longitudinal data and functional analyses would be required to assess the pathogenetic link between gallstone formation and adipokine serum levels.

Key words

gallstones - adipokines - gallbladder - obesity - diabetes

^* These authors contributed equally.

• References

• 1 Lammert F, Sauerbruch T. Mechanisms of Disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 423-433
• 2 Everhart JE, Ruhl CE. Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas. Gastroenterology 2009; 136: 1134-1144
• 3 Everhart JE, Khare M, Hill M et al. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117: 632-639
• 4 Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511
• 5 Aerts R, Penninckx F. The burden of gallstone disease in Europe. Aliment Pharmacol Ther 2003; 18: 49-53
• 6 Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and c-peptide with gallbladder disease. Hepatology 2000; 31: 299-303
• 7 Misciagna G, Guerra V, Di Leo A et al. Insulin and gall stones: a population case control study in southern Italy. Gut 2000; 47: 144-147
• 8 Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 15 368: 230-239
• 9 Shaffer EA. Gallstone Disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006; 20: 981-996
• 10 Schafmayer C, Hartleb J, Tepel J et al. Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. BMC Gastroenterol 2006; 6: 36
• 11 Tsai C-J, Leitzmann MF, Willett WC et al. and Carbohydrate Intake in Relation to Risk of Cholecystectomy in Women. Gastroenterology 2005; 129: 105-112
• 12 Attili AF, Capocaccia R, Carulli N et al. Factors associated with gallstone disease in the MICOL experience. Hepatology 1997; 26: 809-818
• 13 Barbara L, Sama C, Labate AMM et al. A population study on the prevalence of gallstone disease: The sirmione study. Hepatology 1987; 7: 913-917
• 14 The Rome group for epidemiology and prevention of cholelithiasis (GREPCO) . The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. Hepatology 1988; 8: 907-913
• 15 Jørgensen T. Gall stones in a Danish population. Relation to weight, physical activity, smoking, coffee consumption, and diabetes mellitus. Gut 1989; 30: 528-534
• 16 Shiffman ML, Kaplan GD. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995; 122: 899-905
• 17 Syngal S, Coakley EH. Long-term weight patterns and risk for cholecystectomy in women. Ann Intern Med 1999; 130: 471
• 18 Grundy SM. Cholesterol gallstones: a fellow traveler with metabolic syndrome?. Am J Clin Nutr 2004; 80: 1-2
• 19 Kovacs P, Wittenburg H, Kurtz U. Hepatic insulin resistance ties cholesterol formation and the metabolic syndrome. Ann Hepatol 2008; 7: 262-264
• 20 Trujillo ME, Scherer PE. Adipose Tissue-Derived Factors: Impact on Health and Disease. Endocr Rev 2006; 27: 762-778
• 21 Hotta K, Funahashi T, Arita Y et al. Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599
• 22 Hu E, Liang P, Spiegelman BM. AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity. J Biol Chem 1996; 271: 10697-10703
• 23 Ackermann D, Jones J, Barona J et al. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr Res 2011; 31: 197-204
• 24 Bozaoglu K, Bolton K, McMillan J et al. Chemerin Is a Novel Adipokine Associated with Obesity and Metabolic Syndrome. Endocrinology 2007; 148: 4687-4694
• 25 Youn B-S, Bang S-I, Klöting N et al. Serum Progranulin Concentrations May Be Associated With Macrophage Infiltration Into Omental Adipose Tissue. Diabetes 2009; 58: 627-636
• 26 Youn B-S, Klöting N, Kratzsch J et al. Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes. Diabetes 2008; 57: 372-377
• 27 Klöting N, Berndt J, Kralisch S et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436
• 28 Hida K, Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-10615
• 29 Zhang X, Yeung DC, Karpisek M et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes 2008; 57: 1246-1253
• 30 Xu A, Wang Y, Xu JY et al. Protein Is a Plasma Biomarker Closely Associated with Obesity and Metabolic Syndrome. Clin Chem 2006; 52: 405-413
• 31 Wang S, Yeh Y, Yu M et al. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest 2006; 36: 176-180
• 32 Wang S-N, Yeh Y-T, Wang S-T et al. Decreased Retinol Binding Protein 4 Concentrations are Associated With Cholesterol Gallstone Disease. J Formos Med Assoc 2010; 109: 422-429
• 33 Wang SN, Yeh YT, Wang ST et al. Visfatin- a proinflammatory adipokine- in gallstone disease. Am J Surg 2010; 199: 459-465
• 34 Méndez-Sánchez NB-ML, Viñals Y, Chavez-Tapia NC et al. Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol 2005; 11: 6182-6187
• 35 Ogiyama H, Kamada Y, Kiso S et al. Lack of adiponectin promotes formation of cholesterol gallstones in mice. Biochem Biophys Res Commun 2010; 399: 352-358
• 36 Bouchard G, Johnson D, Carver T et al. Cholesterol gallstone formation in overweight mice establishes that obesity per se is not linked directly to cholelithiasis risk. J Lipid Res 2002; 43: 1105-1113
• 37 Hyogo H, Roy S, Cohen DE. Restoration of gallstone susceptibility by leptin in C57BL/6J ob/ob mice. Journal of Lipid Research 2003; 44: 1232-1240
• 38 Ko CW, Beresford SAA, Schulte SJ et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41: 359-365
• 39 Ruhl CE, Everhart JE. Relationship of serum leptin concentration and other measures of adiposity with gallbladder disease. Hepatology 2001; 34: 877-883
• 40 Tönjes A, Koriath M, Schleinitz D et al. Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Human Mol Genet 2009; 18: 4662-4668
• 41 Tonjes A, Zeggini E, Kovacs P et al. Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur J Hum Genet 2010; 18: 104-110
• 42 Veeramah KR, Tonjes A, Kovacs P et al. Genetic variation in the Sorbs of eastern Germany in the context of broader European genetic diversity. Eur J Hum Genet 2011; 19: 995-1001
• 43 American Diabetes Association (ADA) . Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009; 32 (Supplement 1) S62-S67
• 44 Matthews D, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 45 Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D et al. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol 2005; 11: 1653-1657
• 46 Nakeeb A, Comuzzie AG, Al-Azzawi H et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006; 10: 940-948 discussion 948-949
• 47 Biddinger SB, Haas JT, Yu BB et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14: 778-782
• 48 Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935
• 49 Chavez AO, Molina-Carrion M, Abdul-Ghani MA et al. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance. Diabetes Care 2009; 32: 1542-1546
• 50 Uysal KT, Scheja L, Wiesbrock SM et al. Improved Glucose and Lipid Metabolism in Genetically Obese Mice Lacking aP2. Endocrinology 2000; 141: 3388-3396
• 51 Tso AW, Xu A, Sham PC et al. Protein as a New Biomarker Predicting the Development of Type 2 Diabetes. Diabetes Care 2007; 30: 2667-2672
• 52 Berglund ED, Li CY, Bina HA et al. Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity. Endocrinology 2009; 150: 4084-4093
• 53 Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953
• 54 Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295
• 55 Wang SN, Yeh YT, Yu ML et al. Serum adiponectin levels in cholesterol and pigment cholelithiasis. Br J Surg 2006; 93: 981-986
• 56 Nguyen AD, Nguyen TA, Martens LH et al. Progranulin: at the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab. 2013; 24: 597-606
• 57 Ho JC, Ip YC, Cheung ST et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008; 47: 1524-1532
• 58 Frampton G, Ueno Y, Quinn M et al. The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1202-G1211
• 59 Frampton G, Invernizzi P, Bernuzzi F et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012; 61: 268-277
• 60 Purushotham A, Xu Q, Lu J et al. Hepatic Deletion of SIRT1 Decreases Hepatocyte Nuclear Factor 1α/Farnesoid X Receptor Signaling and Induces Formation of Cholesterol Gallstones in Mice. Mol Cell Biol 2012; 32: 1226-1236
• 61 Ouwens DM, Bekaert M, Lapauw B et al. Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch Physiol Biochem 2012; 118: 135-138
• 62 Chakaroun R, Raschpichler M, Klöting N et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012; 61: 706-714
• 63 Mraz M, Bartlova M, Lacinova Z et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol 2009; 71: 369-375
• 64 Maeda K, Cao H, Kono K et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1: 107-119
• 65 Caroli-Bosc FX, Le Gall P, Pugliese P et al. General Practitioners’ Group of Vidauban: Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001; 46: 540-544
• 66 Erichsen R, Frøslev T, Lash TL et al. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol 2011; 173: 162-170
• 67 Smith JL, Roach PD, Wittenberg LN et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000; 15: 871-879